Understanding the symptoms of cirrhosis can facilitate early diagnosis and intervention, improving outcomes for those ...

EnteroBiotix Limited, a clinical-stage biotechnology company focussed on developing best-in-class full-spectrum microbiome therapeutics, announced positive results from its phase 1b IMPuLCE study ...

Complete 3-year clinical data from the MATCH Phase 2 study demonstrate long-term efficacy and safety with autologous, non-engineered macrophages in patients with advanced liver cirrhosis. – New ...

In addition to their ongoing community work, the team will host a Liver Health Check event in Scunthorpe on January 31. Local ...

EBX-102 demonstrated proof-of-principle across multiple microbiome assessments, inflammatory biomarkers and clinical assessments, supporting its cont ...

Cirrhosis is the leading cause of liver transplantation ... Highly Skilled Surgeons and Healthcare Professionals: India has a ...

(ETNB) announced new analyses of data from the Phase 2b ENLIVEN trial evaluating pegozafermin in metabolic dysfunction-associated ...

Primary biliary cholangitis (PBC) has typically been considered a rare condition, with a pooled global estimated incidence of ...

An interferon-free regimen over a 12-week period produced sustained response rates of 83 per cent for people with HCV who had advanced liver cirrhosis and 94 per cent for people who had received ...

The global elastography imaging market is experiencing significant growth, with projections indicating that the industry will ...

In advanced stages, MASH is associated with severe liver diseases, such as cirrhosis, liver cancer and end-stage liver disease, with high mortality. For Dr. Fatima Bosch, “the gene therapy strategy we ...

Results demonstrate statistically significant fibrosis reversal and protection against hepatocellular carcinoma in animal models of MASH –– ...